A low ratio of fPSA/tPSA has been identified as a characteristic of prostate cancer, but the differences in the stabilities of the molecular forms of PSA have cautioned the use of PSA as a primary screening method in the clinic [10]. This evidence concerns the gene KLK3 and Familial prostate cancer.